Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 1.00 |
| ▸ | ADH1B | P00325 | 4/20 | 1.00 |
| ▸ | ADH1A | P07327 | 4/20 | 1.00 |
| ▸ | ADH7 | P40394 | 4/20 | 1.00 |
| ▸ | ADH1C | P00326 | 3/20 | 1.00 |
| ▸ | ADH4 | P08319 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 2/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.45 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.45 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL303653 | 1.00 | EPHX1 (1.00) | EPHX1ADH1BADH1AADH7ADH1C | |
| SCHEMBL145544 | 1.00 | EPHX1 (1.00) | EPHX1ADH1BADH1AADH7ADH1C | |
| SCHEMBL9660807 | 1.00 | EPHX1 (1.00) | EPHX1ADH1BADH1AADH7ADH1C | |
| SCHEMBL9661679 | 1.00 | EPHX1 (1.00) | EPHX1ADH1BADH1AADH7ADH1C | |
| SCHEMBL302735 | 1.00 | EPHX1 (1.00) | EPHX1ADH1BADH1AADH7ADH1C | |
| SCHEMBL9661848 | 1.00 | EPHX1 (1.00) | EPHX1ADH1BADH1AADH7ADH1C | |
| SCHEMBL58363 | 1.00 | — | — | |
| SCHEMBL9658779 | 1.00 | EPHX1 (1.00) | EPHX1ADH1BADH1AADH7ADH1C | |
| SCHEMBL4879688 | 1.00 | EPHX1 (1.00) | EPHX1ADH1BADH1AADH7ADH1C | |
| SCHEMBL149028 | 1.00 | EPHX1 (1.00) | EPHX1ADH1BADH1AADH7ADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240033189-A1 | METHOD FOR PRODUCING A PERSONALIZED COSMETIC PREPARATION | BASF SE (DE) | 2024-02-01 | — | — | US | disclosed |
| US-20230240432-A1 | METHOD FOR PRODUCING PERSONALIZED COSMETICS | BASF SE (DE) | 2023-08-03 | — | — | US | disclosed |
| WO-2023117874-A1 | ENVIRONMENTAL ATTRIBUTES FOR COSMETIC INGREDIENTS | BASF SE (DE) | 2023-06-29 | — | — | WO | disclosed |
| EP-2282735-B1 | PP2A MODULATORS FOR TREATING ALZHEIMER, PARKINSON, DIABETES | SIGNUM BIOSCIENCES INC (US) | 2019-01-16 | — | — | EP | disclosed |
| US-9255070-B2 | Method of deuteration using mixed catalyst | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2016-02-09 | — | — | US | disclosed |
| US-9198432-B2 | 1,2,4-triazolyl-substituted ketoenols | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-01 | — | — | US | disclosed |
| US-9045390-B2 | Haloalkylmethyleneoxyphenyl-substituted ketoenols | BAYER CROPSCIENCE AG (DE) | 2015-06-02 | — | — | US | disclosed |
| US-20140302988-A1 | 1,2,4-Triazolyl-Substituted Ketoenols | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-09 | — | — | US | disclosed |
| US-20140213813-A9 | Haloalkylmethyleneoxyphenyl-Substituted Ketoenols | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-31 | — | — | US | disclosed |
| US-20140031577-A1 | Haloalkylmethyleneoxyphenyl-Substituted Ketoenols | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| US-5047540-A | Platelet Activating Factor Antagonists and Antitumor Agents | SHIONOGI & CO., LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| US-4994453-A | Treating asthma, diabetes, obesity, immunosuppression | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-02-19 | — | — | US | disclosed |
| US-4925849-A | DIURETICS, HYPOTENSIVE AGENTS, CARIOTONIC AGENTS AND ANTIEDEMIC AGENTS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-05-15 | — | — | US | disclosed |
| US-4880576-A | HALOGENATION OF ACIDS, FORMAMIDE CATALYSTS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-11-14 | — | — | US | disclosed |
| EP-0321296-A1 | Lipid derivatives their preparation and use | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1989-06-21 | — | — | EP | disclosed |
| EP-0306025-A2 | Process for producing polyarylene sulfide | IDEMITSU PETROCHEMICAL CO. LTD. (JP) | 1989-03-08 | — | — | EP | disclosed |
| US-4777283-A | Process for the preparation of alkoxycarbonyl isocyanates | BAYER AKTIENGESELLSCHAFT (DE) | 1988-10-11 | — | — | US | disclosed |
| US-4504472-A | MICROBIOCIDES, IMMUNOSTIMULANTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-03-12 | — | — | US | disclosed |
| EP-0050779-B1 | N-ALKYLATED FORMAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE | BAYER AG (DE) | 1984-05-16 | — | — | EP | disclosed |
| EP-0050779-A1 | N-alkylated formamides, process for their preparation and their use | BAYER AG (DE) | 1982-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230240432-A1 | METHOD FOR PRODUCING PERSONALIZED COSMETICS | CUTA, TYR, SUCLG1 | EPHX1 318/4885ADH1B 20/4885ADH1A 200/4885 |
| US-20140302988-A1 | 1,2,4-Triazolyl-Substituted Ketoenols | PIKFYVE, PHYKPL, KCNE1 | EPHX1 1786/4885ADH1B 4351/4885ADH1A 3424/4885 |
| US-20240033189-A1 | METHOD FOR PRODUCING A PERSONALIZED COSMETIC PREPARATION | CUTA, NISCH, TYR | EPHX1 477/4885ADH1B 63/4885ADH1A 514/4885 |
| US-20140213813-A9 | Haloalkylmethyleneoxyphenyl-Substituted Ketoenols | PHYKPL, KCNE1, CSNK1E | EPHX1 506/4885ADH1B 3777/4885ADH1A 3410/4885 |
| US-20140031577-A1 | Haloalkylmethyleneoxyphenyl-Substituted Ketoenols | PHYKPL, KCNE1, CSNK1E | EPHX1 506/4885ADH1B 3777/4885ADH1A 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.